Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RVB 003

Next Previous
Drug Profile

RVB 003

Alternative Names: RVB-003

Latest Information Update: 15 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ResVita Bio
  • Class Anti-inflammatories; Gene therapies; Skin disorder therapies
  • Mechanism of Action Gene transference; KLK5 protein inhibitors; KLK7 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Netherton Syndrome
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Netherton Syndrome

Most Recent Events

  • 09 Jun 2026 ResVita Bio plans a clinical trial for Netherton Syndrome
  • 24 Sep 2025 ResVita Bio announced the successful completion of a face-to-face Pre-IND meeting with the US FDA for RVB-003 for Netherton Syndrome
  • 24 Sep 2025 ResVita Bio plans to file IND application in early 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top